Johnson & Johnson talc-based baby powder sales will soon cease in North America; CMS provides detailed guidance on how to reopen nursing homes to visitors; CDC provides additional information for schools and business looking to resume operations.
Pharmaceutical giant Johnson & Johnson (J&J) will soon halt sales of its controversial talc-based baby powder in the United States and Canada, reports The New York Times. All product currently remaining on store shelves can be sold, but once gone, these supplies will not be replenished. Sales of powder formulations with cornstarch will continue, while the talc-based powder will still be available in other countries. J&J has faced criticism over the years, defending its signature powder from countless lawsuits and claims that it contains asbestos and causes cancer.
Nine pages of guidance from CMS detail how nursing homes can safely reopen to visitors in 3 phases. Phase 1 involves testing all residents and staff, as well as screening staff daily, in addition to facility inspections as necessary. Phase 2 will commence when, among other factors, there have been no new cases for 2 weeks and there are enough personal protective equipment and cleaning supplies; some visitation can also start in the phase. Phase 3 starts when all phase 2 criteria have been met, including no rebound cases. Nursing homes have been especially hard hit by the coronavirus disease 2019 (COVID-19) pandemic, with close to one-third of deaths from the virus being residents or staff at these facilities.
All 50 states have reopened or are starting to, and a revision to a CDC report previously shelved has now been released to help schools, business, and transit systems, as well as numerous other industries, come back online, according to The New York Times. Flexibilty lies at the heart of the 60-page document and centers on providing ongoing testing, depending on risk of exposure to COVID-19; instituting strict rules on hygiene; and coordinating with local health officials on maximum prevention efforts. The report comes on the heels of checklists that the CDC released last week specifically to help school and business make the most informed decisions on when to reopen.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More